pharma · Cystic Fibrosis · Rheumatoid Arthritis · LKFT
Lakefront Biotherapeutics NV
LAVA Therapeutics N.V is a pharma organization headquartered in Utrecht, NL. It trades on NYSE under ticker LKFT. Primary therapeutic focus areas include Cystic Fibrosis, Rheumatoid Arthritis, Ulcerative Colitis, Idiopat
Yalelaan 60, 5th floor, Utrecht 3584 CM, NL HQ
2016 Founded
9 Employees
Public company Type
LKFT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Yalelaan 60, 5th floor, Utrecht 3584 CM, NL
- Founded
- 2016
- Employees
- 9
- Programs
- 99
- Drugs
- 26
- Patents
- 0
GLPG2737
Phase 2 · small molecule · Autosomal Dominant Polycystic Kidney Disease
GLPG2737 for Autosomal Dominant Polycystic Kidney Disease is a Phase 2 program (small_molecule) at Lakefront Biotherapeutics NV with 1 ClinicalTrials.gov record(s).
Internal code GLPG2737-CL-203
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Lakefront Biotherapeutics NV
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Autosomal Dominant Polycystic Kidney Disease
- Status
- terminated
- Trials
- 1